A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer

This publication has 6 references indexed in Scilit:

• A reality check of the accelerated approval of immune-checkpoint inhibitors
  Nature Reviews Clinical Oncology, 2019
• Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
  JAMA Internal Medicine, 2019
• A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
  European Journal of Cancer, 2019
• First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
  Nature Reviews Drug Discovery, 2018
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
  The Lancet Oncology, 2016